Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.64 |
| ▸ | IDO1 | P14902 | 3/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041609 | 0.86 | TGFBR1 (0.61) | TGFBR1IDO1TGFBR2DYRK1AMAPK14 | |
| SCHEMBL18041595 | 0.83 | TGFBR1 (0.91) | TGFBR1TGFBR2DYRK1AMAPK14 | |
| SCHEMBL18041605 | 0.81 | TGFBR1 (0.59) | TGFBR1RETTGFBR2DYRK1AMAPK14 | |
| SCHEMBL15639720 | 0.79 | TGFBR1 (0.58) | TGFBR1RETTGFBR2DYRK1A | |
| SCHEMBL18041535 | 0.79 | TGFBR1 (0.49) | TGFBR1RETTGFBR2DYRK1AMAPK14 | |
| SCHEMBL18042075 | 0.79 | TGFBR1 (0.71) | TGFBR1TGFBR2DYRK1AMAPK14KDM4E | |
| SCHEMBL27335379 | 0.75 | IDO1 (0.80) | IDO1MAPK14BRAFKDM4ECYP3A4 | |
| SCHEMBL18042041 | 0.74 | TGFBR1 (0.52) | TGFBR1RETTGFBR2DYRK1AKDM4E | |
| SCHEMBL18041942 | 0.71 | TGFBR1 (0.67) | TGFBR1IDO1TGFBR2DYRK1AMAPK14 | |
| SCHEMBL17767505 | 0.70 | TGFBR1 (0.44) | TGFBR1RETTGFBR2DYRK1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | claimed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | claimed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | claimed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | claimed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885IDO1 295/4885RET 93/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885IDO1 295/4885RET 93/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885IDO1 295/4885RET 93/4885 |
| US-10287295-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885IDO1 305/4885RET 81/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885IDO1 295/4885RET 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.